Alto Neuroscience, Inc. (ANRO) Price & Analysis

Compare

471 Followers

ANRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.60 - $15.04

Previous CloseN/A

Volume104.17K

Average Volume (3M)112.05K

Market Cap

$112.37M

Enterprise Value-$60.72M

Total Cash (Recent Filing)$147.59M

Total Debt (Recent Filing)$4.21M

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Nov 18, 2025

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding27,076,630

10 Day Avg. Volume101,696

30 Day Avg. Volume112,045

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.54

Enterprise Value/Revenue-154.11

Enterprise Value/Gross Profit221.60

Enterprise Value/Ebitda0.95

Forecast

1Y Price Target

$10.40

Price Target Upside150.60% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe financial position is strong, with a cash runway estimated to last until 2028, which provides stability for continued operations and research.

Market PotentialThe market acceptance and experience of esketamine, marketed as SPRAVATO by Johnson & Johnson, highlights potential for ANRO's offerings in treatment-resistant depression and major depressive disorder.

Pipeline DevelopmentANRO's pipeline includes ALTO-300, ALTO-207, and ALTO-101 with a focus on upcoming clinical catalysts.

Bears Say

Clinical Trial RisksThe negative or mixed data readouts from CNS companies highlight the high development risk in the space.

Financial PerformanceANRO reported a net loss of $17.7M in the second quarter of 2025, reflecting financial challenges despite a strong cash position.

Product Efficacy ConcernsThe lack of improvement over placebo on BL-VAS means analysts are less confident in ALTO-203's potential in MDD with anhedonia and are decreasing the probability of success to 2.5% from 5%.

Alto Neuroscience, Inc. News

Promising Pipeline and Expert Backing Drive Buy Rating for Alto Neuroscience, Inc.

JonesTrading analyst Justin Walsh has maintained their bullish stance on ANRO stock, giving a Buy rating on August...

7d ago

ANRO

Alto Neuroscience: Strategic Pipeline Expansion and Strong Financial Position Justify Buy Rating

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Alto Neuroscience, Inc.. The associated price...

10d ago

ANRO

Alto Neuroscience, Inc.: Promising Pipeline and Financial Stability Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating today....

14d ago

ANRO

Alto Neuroscience Advances Pipeline Amidst Strong Cash Position

Alto Neuroscience, Inc. ( ($ANRO) ) has released its Q2 earnings. Here is a breakdown of the information...

14d ago

ANRO

Alto Neuroscience Appoints Dr. Sanchez to Board

Alto Neuroscience, Inc. ( ($ANRO) ) has provided an update. On August 12, 2025, Alto Neuroscience, Inc. announced...

15d ago

ANRO

Alto Neuroscience Faces Legal Storm Over Drug Claims

Alto Neuroscience, Inc. finds itself embroiled in a legal battle that could have significant repercussions for its investors....

29d ago

ANRO

Alto Neuroscience highlights study results guiding ALTO-207 development

Alto Neuroscience (ANRO) highlighted the publication of data from the PAX-D study in The Lancet Psychiatry, evaluating pramipexole...

2M ago

ANRO

Optimistic Buy Rating for Alto Neuroscience Amid Promising ALTO-203 Developments and Strategic Opportunities

William Blair analyst Myles Minter has reiterated their bullish stance on ANRO stock, giving a Buy rating today....

2M ago

ANRO

Promising Phase 2 Results for ALTO-203 in Treating Anhedonia-MDD Justify Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report),...

2M ago

ANRO

Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results

Alto Neuroscience (ANRO) announced the identification of a patient selection biomarker and pharmacodynamic results from its exploratory Phase...

2M ago

ANRO

Alto Neuroscience Reports Positive Phase 2 Trial Results

Alto Neuroscience, Inc. ( ($ANRO) ) has issued an announcement. On June 26, 2025, Alto Neuroscience announced positive...

2M ago

ANRO

Promising Future for Alto Neuroscience: Strategic Acquisition and Strong Financial Position Drive Buy Rating

Jefferies analyst Andrew Tsai maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) on June...

3M ago

ANRO

Alto Neuroscience acquires dopamine agonist combination candidate

Alto Neuroscience (ANRO) entered into an asset purchase agreement with Chase Therapeutics for a portfolio of potentially best-in-class...

3M ago

ANRO

Alto Neuroscience presents new data at Society of Biological Psychiatry meeting

Alto Neuroscience (ANRO) announced multiple presentations at the Society of Biological Psychiatry annual meeting, in Toronto, Canada, held...

4M ago

ANRO

ANRO FAQ

What was Alto Neuroscience, Inc.’s price range in the past 12 months?

Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $15.04 in the past 12 months.

What is Alto Neuroscience, Inc.’s market cap?

Alto Neuroscience, Inc.’s market cap is $112.37M.

When is Alto Neuroscience, Inc.’s upcoming earnings report date?

Alto Neuroscience, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 82 days.

How were Alto Neuroscience, Inc.’s earnings last quarter?

Alto Neuroscience, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.599 by -$0.051.

Is Alto Neuroscience, Inc. overvalued?

According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alto Neuroscience, Inc. pay dividends?

Alto Neuroscience, Inc. does not currently pay dividends.

What is Alto Neuroscience, Inc.’s EPS estimate?

Alto Neuroscience, Inc.’s EPS estimate is -0.69.

How many shares outstanding does Alto Neuroscience, Inc. have?

Alto Neuroscience, Inc. has 27,076,630 shares outstanding.

What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?

Alto Neuroscience, Inc. reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.599. Following the earnings report the stock price went down -0.319%.

Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?

Currently, no hedge funds are holding shares in ANRO

Alto Neuroscience, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-42.78%

Trailing 12-Months

Asset Growth

-20.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (ANRO) is a biotechnology company focused on developing precision medicine approaches for the treatment of mental health disorders. The company leverages advancements in brain biomarkers and artificial intelligence to create personalized treatment plans for conditions such as depression and anxiety. By integrating cutting-edge neuroscience with clinical data, Alto aims to provide effective and targeted therapeutic solutions.

Alto Neuroscience, Inc. (ANRO) Earnings & Revenues

Historic Earnings Reports

ANRO Stock 12 Month Forecast

Average Price Target

$10.40

▲(150.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.05,3.969230769230769,4.888461538461538,5.8076923076923075,6.726923076923077,7.646153846153846,8.565384615384616,9.484615384615385,10.403846153846153,11.323076923076922,12.24230769230769,13.16153846153846,14.080769230769231,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.05,3.615384615384615,4.180769230769231,4.746153846153846,5.311538461538461,5.8769230769230765,6.442307692307692,7.007692307692308,7.573076923076923,8.138461538461538,8.703846153846154,9.26923076923077,9.834615384615384,{"y":10.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.05,3.123076923076923,3.196153846153846,3.269230769230769,3.342307692307692,3.4153846153846152,3.4884615384615385,3.5615384615384613,3.6346153846153846,3.707692307692308,3.7807692307692307,3.853846153846154,3.926923076923077,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >